Financials Cash flow from operating activities came in at SEK -44m (SEK -32.8m in Q1’22). Cash and cash equivalents amounted SEK 322.6m (SEK 368m in Q1’22). IRLAB has an estimated cash runway to cover 12 more months.
Share price implications With no major news in the report, we expect a neutral share price reaction today. The main upcoming milestone is the top-line data from the mesdopetam Ph 2b trial in PD-LIDs by YE’22e. IRLAB will host a presentation today at 10:00 CET viewable at: https://youtu.be/NHxs1EViwIM.
Läs mer på ABG Sundal Collier
Aktuellt
SENASTE
